碘^(125)粒子近距离照射联合内分泌疗法治疗前列腺癌

Research of curative effect in patients with prostate cancer by ^(125)I implantation with endocrine therapy

目的:探讨碘^(125)粒子近距离照射联合内分泌疗法治疗前列腺癌的疗效。方法:按照否接受碘^(125)粒子近距离照射治疗将60例前列腺癌患者分为观察组30例和对照组30例,对照组患者给予内分泌疗法治疗,观察组患者在此基础上加用碘^(125)粒子近距离照射治疗,比较两组治疗效果。结果:观察组患者治疗后6个月前列腺体积小于对照组,差异有统计学意义(P<0.05);观察组患者治疗后1、3、6个月KPS评分均高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后1、3、6、12个月血清前列腺特异性抗原(PSA)水平均低于对照组,差异有统计学意义(P<0.05);观察组患者治疗后6、12个月总有效率均显著高于对照组,差异有统计学意义(P<0.05);两组患者治疗后1、2、3年生存率对比,差异无统计学意义(P>0.05)。结论:碘^(125)粒子近距离照射联合内分泌疗法治疗前列腺癌疗效显著,可有效改善患者PSA水平和KPS评分。

Objective To explore the curative effect in patients with prostate cancer by E25I implantation with endocrine therapy. Methods Sixty cases of patients with prostate cancer were divided into the experiment group （30 cases） and the control group （30 cases） with or without 125I implantation. The control group were treated by endocrine therapy, the experiment group were treated by 125I implantation based on endocrine therapy. The curative effect were observed. Results The volume of prostate inthe experiment group after 6 month treatment were smaller than that in the control group （P〈0.05）; The KPS score in the experiment group after 1, 3, 6 months treatment were higher than that of the control group （P〈0.05）; The level of PSAin the experiment group after 1, 3, 6, 12 months treatment were lower than that in the control group （P〈0.05）. The total effect in the experiment group after 6, 12 month treatment were higher than that in the control group （P〈0.05）. There had no significant difference on the survival rate after 1, 2, 3 years treatment in the two groups （P〈0.05）. Conclusion It has significant efficacy in patients with prostate cancer by 125I implantation with endocrine therapy which can improve the level of PSA and KPS scores. The long-term survival situation is satisfactory. This method is worth of generalization in clinic.